

BIOMARIN PHARMACEUTICAL INC

Form 4

March 17, 2017

**FORM 4****UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287  
 Expires: January 31, 2005  
 Estimated average burden hours per response... 0.5

Check this box  
 if no longer  
 subject to  
 Section 16.  
 Form 4 or  
 Form 5  
 obligations  
 may continue.  
*See Instruction*  
 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF  
SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,  
 Section 17(a) of the Public Utility Holding Company Act of 1935 or Section  
 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
**BIENAIME JEAN JACQUES**

(Last) (First) (Middle)

C/O BIOMARIN  
 PHARMACEUTICAL INC., 770  
 LINDARO ST.

(Street)

SAN RAFAEL, CA 94901

(City) (State) (Zip)

2. Issuer Name **and** Ticker or Trading  
 Symbol

**BIOMARIN PHARMACEUTICAL  
 INC [BMRN]**

3. Date of Earliest Transaction  
 (Month/Day/Year)  
 03/15/2017

4. If Amendment, Date Original  
 Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to  
 Issuer

(Check all applicable)

☐ X Director ☐ 10% Owner  
☒ X Officer (give title below) ☐ Other (specify below)  
 Chief Executive Officer

6. Individual or Joint/Group Filing(Check  
 Applicable Line)  
☒ X Form filed by One Reporting Person  
☐ Form filed by More than One Reporting  
 Person

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D) Price			
Common Stock	03/15/2017 <sup>(1)</sup>	03/15/2017	M		5,000	A \$ 17.33	211,364	D	
Common Stock	03/15/2017 <sup>(1)</sup>	03/15/2017	S		5,000	D \$ 91.42 <sup>(2)</sup>	206,364	D	
Common Stock	03/15/2017	03/15/2017	F		15,690	D \$ 92.5	190,674	D	
Common Stock	03/16/2017 <sup>(1)</sup>	03/16/2017	M		5,000	A \$ 71.33	195,674	D	

Edgar Filing: BIOMARIN PHARMACEUTICAL INC - Form 4

Common Stock	03/16/2017 <sup>(1)</sup>	03/16/2017	S	5,000	D	\$ 91.96 <sup>(2)</sup>	190,674	D
-----------------	---------------------------	------------	---	-------	---	-------------------------------	---------	---

Common Stock							182,801	I	Shares held by Jean-Jacques Bienaime Family Trust
-----------------	--	--	--	--	--	--	---------	---	---

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

SEC 1474  
(9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**  
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)	
				Code	V (A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to buy Common Stock)	\$ 17.33	03/15/2017 <sup>(1)</sup>	03/15/2017	M	5,000	12/07/2007	06/06/2017	Common Stock	5,000
Stock Option (Right to buy Common Stock)	\$ 17.33	03/16/2017 <sup>(1)</sup>	03/16/2017	M	5,000	12/07/2007	06/06/2017	Common Stock	5,000

## Reporting Owners

Reporting Owner Name / Address

Relationships

Director 10% Owner Officer Other

BIENAIME JEAN JACQUES  
C/O BIOMARIN PHARMACEUTICAL INC.  
770 LINDARO ST.  
SAN RAFAEL, CA 94901

X

Chief Executive Officer

## Signatures

/s/ Laura Randall Woodhead,  
Attorney-in-Fact

03/17/2017

\_\_Signature of Reporting Person

Date

## Explanation of Responses:

- \* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Trade made pursuant to a 10b5-1 plan executed on November 15, 2016.
- (2) All shares were sold at the same price.
- (3) Reflects the number of stock options outstanding after the transaction from this specific stock option grant.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.  
Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.